The Maudsley Prescribing Guidelines in Psychiatry
by Taylor, David; Paton, Carol; Kapur, ShitijEdition: 11th
Format: Paperback
Pub. Date: 2012-04-02
Publisher(s): Wiley-Blackwell
Other versions by this Author
List Price: $94.50
Rent Textbook
Select for Price
New Textbook
We're Sorry
Sold Out
Used Textbook
We're Sorry
Sold Out
eTextbook
We're Sorry
Not Available
How Marketplace Works:
- This item is offered by an independent seller and not shipped from our warehouse
- Item details like edition and cover design may differ from our description; see seller's comments before ordering.
- Sellers much confirm and ship within two business days; otherwise, the order will be cancelled and refunded.
- Marketplace purchases cannot be returned to eCampus.com. Contact the seller directly for inquiries; if no response within two days, contact customer service.
- Additional shipping costs apply to Marketplace purchases. Review shipping costs at checkout.
Summary
The highly respected Maudsley Prescribing Guidelines are updated and revised in this new edition of a popular text.
Author Biography
David Taylor, Director of Pharmacy and Pathology at the South London and Maudsley NHS Foundation Trust, Denmark Hill; Professor of Psychopharmacology, King's College London, London, UK Carol Pawn, Chief Pharmacist at Oxleas NHS Foundation Trust, Dartford, Kent, UK Shitij Kapur, Professor of Schizophrenia, Imaging and Therapeutics and the Dean and Head of School at the Institute of Psychiatry, King's College London Institute of Psychiatry, Denmark Hill, London, UK
Table of Contents
| Preface | p. ix |
| Acknowledgements | p. x |
| Notes on using The Maudsley Prescribing Guidelines | p. xi |
| Notes on inclusion of drugs | p. xi |
| List of abbreviations | p. xii |
| Plasma level monitoring of psychotropic drugs and anticonvulsants | p. 1 |
| Interpreting sample results | p. 2 |
| Schizophrenia | p. 11 |
| Antipsychotic drugs | p. 11 |
| Antipsychotic drugs: equivalent doses | p. 13 |
| Antipsychotic drugs: minimum effective doses | p. 14 |
| Antipsychotic drugs: licensed maximum doses | p. 16 |
| New antipsychotic drugs | p. 17 |
| Antipsychotic drugs: general principles of prescribing | p. 21 |
| National Institute for Health and Clinical Excellence guidelines for the treatment of schizophrenia | p. 22 |
| Treatment algorithms for schizophrenia | p. 24 |
| Antipsychotic drugs: monitoring of metabolic effects | p. 26 |
| Switching antipsychotic drugs because of poor tolerability | p. 31 |
| Antipsychotic response: to increase the dose, to switch, to add or just wait-what is the right move? | p. 33 |
| Speed and onset of antipsychotic drug action | p. 36 |
| First-generation antipsychotic drugs: place in therapy | p. 39 |
| Antipsychotic drugs: long-acting injections | p. 40 |
| Risperidone long-acting injection | p. 44 |
| Paliperidone palmitate long-acting injection | p. 47 |
| Management of patients on long-term depots: dose reduction | p. 50 |
| Combined antipsychotic drugs | p. 51 |
| High-dose antipsychotic drugs: prescribing and monitoring | p. 54 |
| Negative symptoms in schizophrenia | p. 57 |
| Antipsychotic prophylaxis | p. 60 |
| Refractory schizophrenia and clozapine | p. 64 |
| Clozapine augmentation | p. 66 |
| Refractory schizophrenia: alternatives to clozapine | p. 69 |
| Clozapine: management of common adverse effects | p. 75 |
| Clozapine: uncommon or unusual adverse effects | p. 78 |
| Clozapine: serious haematological and cardiovascular adverse effects | p. 80 |
| Clozapine, neutropenia and lithium | p. 84 |
| Clozapine and chemotherapy | p. 88 |
| Clozapine-related hypersalivation | p. 89 |
| Guidelines for the initiation of clozapine for patients based in the community | p. 92 |
| Omega-3 fatty acids fish oils in schizophrenia | p. 96 |
| Extrapyramidal side-effects of antipsychotic drug treatment | p. 98 |
| Treatment of antipsychotic-induced akathisia | p. 103 |
| Treatment of tardive dyskinesia | p. 105 |
| Neuroleptic malignant syndrome | p. 110 |
| Catatonia | p. 113 |
| Cardiovascular effects of antipsychotic drug treatment | p. 115 |
| Antipsychotic drugs and hypertension | p. 122 |
| Hyperprolactinaemia | p. 123 |
| Antipsychotic-induced weight gain | p. 126 |
| Treatment of drug-induced weight gain | p. 128 |
| Antipsychotic drugs, diabetes and impaired glucose tolerance | p. 132 |
| Antipsychotic drugs and dyslipidaemia | p. 138 |
| Antipsychotic drugs and sexual dysfunction | p. 142 |
| Antipsychotic-associated hyponatraemia | p. 148 |
| Antipsychotics and pneumonia | p. 150 |
| Relative adverse effects of antipsychotic drugs: a rough guide | p. 151 |
| Bipolar disorder | p. 153 |
| Valproate | p. 153 |
| Lithium | p. 159 |
| Carbamazepine | p. 168 |
| Physical monitoring of people with bipolar disorder | p. 173 |
| Treatment of acute mania or hypomania | p. 176 |
| Antipsychotic drugs in bipolar disorder | p. 182 |
| Bipolar depression | p. 185 |
| Rapid cycling bipolar disorder | p. 191 |
| Prophylaxis in bipolar disorder | p. 193 |
| Depression and anxiety | p. 197 |
| Depression | p. 197 |
| Antidepressants | p. 201 |
| Treatment of resistant depression | p. 222 |
| Treatment of psychotic depression | p. 233 |
| Electroconvulsive therapy and psychotropic drugs | p. 235 |
| Psychostimulants in depression | p. 239 |
| Treatment of depression in the elderly | p. 243 |
| Treatment of depression in stroke | p. 247 |
| Adverse effects of antidepressants | p. 249 |
| Selective serotonin reuptake inhibitors and bleeding | p. 252 |
| Depression and diabetes | p. 255 |
| Cardiac effects of antidepressants | p. 257 |
| Antidepressants and sexual dysfunction | p. 264 |
| Antidepressants and hyperprolactinaemia | p. 268 |
| Antidepressants: swapping and stopping | p. 270 |
| St John's wort in the treatment of depression | p. 278 |
| Drug interactions with antidepressants | p. 281 |
| Alternative routes of administration for antidepressants | p. 286 |
| Anxiety spectrum disorders | p. 292 |
| Benzodiazepines in the treatment of psychiatric disorders | p. 301 |
| Benzodiazepines and disinhibition | p. 304 |
| Benzodiazepines: dependence and detoxification306 | |
| Insomnia | p. 310 |
| Children and adolescents | p. 315 |
| Principles of prescribing practice in childhood and adolescence | p. 315 |
| Depression in children and adolescents | p. 316 |
| Bipolar illness in children and adolescents | p. 321 |
| Psychosis in children and adolescents | p. 326 |
| Anxiety in children and adolescents | p. 327 |
| Obsessive compulsive disorder in children and adolescents | p. 328 |
| Attention deficit hyperactivity disorder | p. 332 |
| Autism spectrum disorders | p. 337 |
| Tics and Tourette's syndrome | p. 345 |
| Melatonin in the treatment of insomnia in children and adolescents | p. 349 |
| Rapid tranquillisation in children and adolescents | p. 351 |
| Doses of commonly used psychotropic drugs in children and adolescents | p. 354 |
| Substance misuse | p. 355 |
| Alcohol dependence | p. 356 |
| Opioid misuse and dependence | p. 372 |
| Nicotine and smoking cessation | p. 398 |
| Stimulant drugs of dependence | p. 406 |
| Benzodiazepine misuse | p. 407 |
| ¿ -Butaryl-lactone and ¿ -hydroxybutyrate dependence | p. 408 |
| Drugs of misuse: a summary | p. 410 |
| Interactions between 'street drugs' and prescribed psychotropic drugs | p. 414 |
| Use of psychotropic drugs in special patient groups | p. 419 |
| Epilepsy | p. 419 |
| Pregnancy | p. 430 |
| Breast feeding | p. 446 |
| Renal impairment | p. 462 |
| Hepatic impairment | p. 478 |
| Prescribing in the elderly | p. 487 |
| Dementia | p. 490 |
| Behavioural and psychological symptoms of dementia | p. 509 |
| Parkinson's disease | p. 518 |
| Multiple sclerosis | p. 522 |
| Eating disorders | p. 527 |
| Acutely disturbed or violent behaviour | p. 531 |
| Psychotropic medications for adults with learning disabilities | p. 539 |
| Borderline personality disorder | p. 545 |
| Delirium | p. 547 |
| Huntington's disease | p. 554 |
| Psychotropic drugs and surgery | p. 558 |
| Prescribing psychotropic drugs for patients with HIV infection | p. 564 |
| Psychotropic drugs and cytochrome CYP function | p. 573 |
| Summary of psychiatric side-effects of non-psychotropic drugs | p. 578 |
| Miscellaneous conditions and substances | p. 587 |
| Psychotropic drugs in overdose | p. 587 |
| Biochemical and haematological effects of psychotropic drugs | p. 593 |
| Prescribing drugs outside their licensed indications | p. 604 |
| Observations on the placebo effect in mental illness | p. 606 |
| Drug interactions with alcohol | p. 608 |
| Nicotine | p. 613 |
| Smoking and psychotropic drugs | p. 616 |
| Caffeine | p. 618 |
| Complementary therapies | p. 624 |
| Enhancing medication adherence | p. 628 |
| Driving and psychotropic medicines | p. 634 |
| Covert administration of medicines within food and drink | p. 643 |
| Index | p. 647 |
| Table of Contents provided by Ingram. All Rights Reserved. |
An electronic version of this book is available through VitalSource.
This book is viewable on PC, Mac, iPhone, iPad, iPod Touch, and most smartphones.
By purchasing, you will be able to view this book online, as well as download it, for the chosen number of days.
Digital License
You are licensing a digital product for a set duration. Durations are set forth in the product description, with "Lifetime" typically meaning five (5) years of online access and permanent download to a supported device. All licenses are non-transferable.
More details can be found here.
A downloadable version of this book is available through the eCampus Reader or compatible Adobe readers.
Applications are available on iOS, Android, PC, Mac, and Windows Mobile platforms.
Please view the compatibility matrix prior to purchase.